Novavax, Inc. (NASDAQ:NVAX) headquartered in Gaithersburg, will host a conference call for the investment community to discuss the 3Q20 earnings result on 9th November 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.novavax.com
Earnings Expectation
Novavax, Inc. is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, NVAX is expected to report 3Q20 income of $ 1.73 per share from revenue of $ 230.56 million. For the full year, analysts anticipate top line of $ 971.44 million, while looking forward to income of $ 6.97 per share bottom line.
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The companys lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen.
